Beyond Bioprinting

The 3D bioprinting sector has failed to deliver on its expectations of providing solutions within the regenerative medicine industry. Beyond many publications from this sector, we have none to very limited regenerative medicine applications coming to the market. The reason that the bioprinting field is failing is due to technological limitations. At current, the available bioprinters are not able to create applications that can enhance the abilities to diagnose, monitor and or treat diseases.

January 2025, 12th edition, The Netherlands

Home | Programme | Speakers | Exhibit | Registration | Partners | Conference Topics | Venue | Conference News | Previous editions

For example, create applications that can be used to analyze the safety and efficacy of pharmaceutical (bio)molecules in companies’ development pipelines. Their shortcomings are either based on a lack of processing speed, their inability to keep the cells intact and functional, or their limitation in creating the tissue complexity that is needed to create realistic human tissue. Beyond the realistic functionality of these tissues, they also lack additional functionality in terms of real-time output to measure certain conditions or processes within the tissue itself. In order to transform this industry we need to go Beyond Bioprinting. Biofabrication of complete transplantable complex organs will be decades away but we are already presented with the opportunity to create solutions for the regenerative medicine industry by merging different technologies such as 4D bioprinting and for example cyborganic technology.

A presentation by John Zandbergen, CEO of Ourobionics.

What drives the John!
He believes that by merging the right technology together we can finally come to solutions and make up for the promises made since the first moment bioprinting became a reality such as ending animal trials and providing potential methods for restoring or repairing organ function.

About John Zandbergen
Over 20 years of experience in International business management within the Lifescience, IVD, and MedTech industries. For over the last 10 years, I have consulted for numerous companies of which one was a company developing and manufacturing 3D printers. One of their projects was to build a 3D printer that could print living cells in 3D. This journey has led to co-founding Ourobionics where we focus to go beyond bioprinting.

About Ourobionics BV
Ourobionics has advanced bioelectric fabrication technology which we use to make complex human tissue embedded with bioelectronics and disease biosensors with standardized readouts to speed up drug discovery, replace animal testing and make future therapies.
For more information go to the website.

John Zandbergen will speak at the 2023 edition of the 3D Medical Conference.